1887

Abstract

Intrapartum chemoprophylaxis for pregnant group B streptococcus (GBS) carriers reduces vertical transmission, with a resultant decrease in neonatal as well as maternal morbidity from invasive GBS infection. Current Australian guidelines recommend penicillin for intrapartum prophylaxis of GBS carriers, with erythromycin or clindamycin for those with a -lactam allergy. Recent reports globally suggest that resistance to erythromycin and clindamycin may be increasing; hence, a study was undertaken to promote an evidence base for local clinical guidelines. Samples collected for standardized susceptibility testing included 1160 invasive GBS isolates (264 isolates retrospectively from 1982 to 2001 and prospectively from 2002 to 2006, plus 896 prospectively collected colonizing GBS isolates gathered over a 12 month period from 2005 to 2006) from 16 laboratories around Australia. All isolates displaying phenotypic macrolide or lincosamide resistance were subsequently genotyped. No isolates showed reduced susceptibility to penicillin or vancomycin. Of the invasive isolates, 6.4 % demonstrated phenotypic erythromycin resistance and 4.2 % were clindamycin resistant. Of the erythromycin-resistant isolates, 53 % showed cross-resistance to clindamycin. Very similar results were found in colonizing specimens. There was no statistically significant change in macrolide-resistance rates over the two study periods 1982–2001 and 2002–2006. Genotyping for macrolide and lincosamide-resistant isolates was largely consistent with phenotype. These findings suggest that penicillin therapy remains an appropriate first-line antibiotic choice for intrapartum GBS chemoprophylaxis, with erythromycin and/or clindamycin resistance being low in the Australian population. It would, nevertheless, be appropriate for laboratories screening for GBS in obstetric patients to consider macrolide sensitivity testing, particularly for those with -lactam allergy, to ensure appropriate chemoprophylaxis.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.022616-0
2011-02-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/2/230.html?itemId=/content/journal/jmm/10.1099/jmm.0.022616-0&mimeType=html&fmt=ahah

References

  1. AEG 2010 Therapeutic Guidelines: Antibiotic, version 14 Melbourne: Therapeutic Guidelines Limited;
    [Google Scholar]
  2. Andrews J. I., Diekema D. J., Hunter S. K., Rhomberg P. R., Pfaller M. A., Jones R. N., Doern G. V. 2000; Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the western hemisphere. Am J Obstet Gynecol 183:859–862 [CrossRef]
    [Google Scholar]
  3. Anthony B. F. 1982; Carriage of group B streptococci during pregnancy: a puzzler. J Infect Dis 145:789–793 [CrossRef]
    [Google Scholar]
  4. Baker C. J., Barrett F. F. 1973; Transmission of group B streptococci among parturient women and their neonates. J Pediatr 83:919–925 [CrossRef]
    [Google Scholar]
  5. Bergseng H., Rygg M., Bevanger L., Bergh K. 2008; Invasive group B streptococcus (GBS) disease in Norway 1996–2006. Eur J Clin Microbiol Infect Dis 27:1193–1199 [CrossRef]
    [Google Scholar]
  6. Castor M. L., Whitney C. G., Como-Sabetti K., Facklam R. R., Ferrieri P., Bartkus J. M., Juni B. A., Cieslak P. R., Farley M. M. other authors 2008; Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008:727505
    [Google Scholar]
  7. CDC 2007; Perinatal group B streptococcal disease after universal screening recommendations – United States, 2003–2005. MMWR Morb Mortal Wkly Rep 56:701–705
    [Google Scholar]
  8. CLSI 2006 Performance Standards for Antimicrobial Susceptibility Testing , supplement M100-S16 Wayne, PA: Clinical and Laboratory Standards Institute;
    [Google Scholar]
  9. Daley A. J., Garland S. M. 2004; Prevention of neonatal group B streptococcal disease: progress, challenges and dilemmas. J Paediatr Child Health 40:664–668 [CrossRef]
    [Google Scholar]
  10. Daley A. J., Isaacs D. 2004; Ten-year study on the effect of intrapartum antibiotic prophylaxis on early onset group B streptococcal and Escherichia coli neonatal sepsis in Australasia. Pediatr Infect Dis J 23:630–634 [CrossRef]
    [Google Scholar]
  11. Desjardins M., Delgaty K. L., Ramotar K., Seetaram C., Toye B. 2004; Prevalence and mechanisms of erythromycin resistance in group A and group B streptococcus: implications for reporting susceptibility results. J Clin Microbiol 42:5620–5623 [CrossRef]
    [Google Scholar]
  12. DiPersio L. P., DiPersio J. R. 2006; High rates of erythromycin and clindamycin resistance among OBGYN isolates of group B streptococcus. Diagn Microbiol Infect Dis 54:79–82 [CrossRef]
    [Google Scholar]
  13. Figueira-Coelho J., Ramirez M., Salgado M. J., Melo-Cristino J. 2004; Streptococcus agalactiae in a large Portuguese teaching hospital: antimicrobial susceptibility, serotype distribution, and clonal analysis of macrolide-resistant isolates. Microb Drug Resist 10:31–36 [CrossRef]
    [Google Scholar]
  14. Fitoussi F., Loukil C., Gros I., Clermont O., Mariani P., Bonacorsi S., Le Thomas I., Deforche D., Bingen E. 2001; Mechanisms of macrolide resistance in clinical group B streptococci isolated in France. Antimicrob Agents Chemother 45:1889–1891 [CrossRef]
    [Google Scholar]
  15. Garland S. M. 1991; Early onset neonatal group B streptococcus (GBS) infection: associated obstetric risk factors. Aust N Z J Obstet Gynaecol 31:117–118 [CrossRef]
    [Google Scholar]
  16. Garland S. M., Fliegner J. R. 1991; Group B streptococcus (GBS) and neonatal infections: the case for intrapartum chemoprophylaxis. Aust N Z J Obstet Gynaecol 31:119–122 [CrossRef]
    [Google Scholar]
  17. Gerhardt P., Krieg N., Murray R. 1994 Methods for General and Molecular Bacteriology Washington, DC: American Society for Microbiology;
    [Google Scholar]
  18. Hsueh P. R., Teng L. J., Lee L. N., Ho S. W., Yang P. C., Luh K. T. 2001; High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan. Antimicrob Agents Chemother 45:3205–3208 [CrossRef]
    [Google Scholar]
  19. Janapatla R. P., Ho Y. R., Yan J. J., Wu H. M., Wu J. J. 2008; The prevalence of erythromycin resistance in group B streptococcal isolates at a University Hospital in Taiwan. Microb Drug Resist 14:293–297 [CrossRef]
    [Google Scholar]
  20. Malbruny B., Werno A. M., Anderson T. P., Murdoch D. R., Leclercq R. 2004; A new phenotype of resistance to lincosamide and streptogramin A-type antibiotics in Streptococcus agalactiae in New Zealand. J Antimicrob Chemother 54:1040–1044 [CrossRef]
    [Google Scholar]
  21. Marimón J. M., Valiente A., Ercibengoa M., García-Arenzana J. M., Pérez-Trallero E. 2005; Erythromycin resistance and genetic elements carrying macrolide efflux genes in Streptococcus agalactiae . Antimicrob Agents Chemother 49:5069–5074 [CrossRef]
    [Google Scholar]
  22. Matsubara K., Nishiyama Y., Katayama K., Yamamoto G., Sugiyama M., Murai T., Baba K. 2001; Change of antimicrobial susceptibility of group B streptococci over 15 years in Japan. J Antimicrob Chemother 48:579–582 [CrossRef]
    [Google Scholar]
  23. Moyo S. R., Maeland J. A., Munemo E. S. 2001; Susceptibility of Zimbabwean Streptococcus agalactiae (group B streptococcus; GBS) isolates to four different antibiotics. Cent Afr J Med 47:226–229
    [Google Scholar]
  24. Palasanthiran P., Starr M., Jones C. (editors) 2002 Management of Perinatal Infections Sydney: Australasian Society for Infectious Diseases;
    [Google Scholar]
  25. Peláez L. M., Gelber S. E., Fox N. S., Chasen S. T. 2009; Inappropriate use of vancomycin for preventing perinatal group B streptococcal (GBS) disease in laboring patients. J Perinat Med 37:487–489
    [Google Scholar]
  26. RANZCOG 2007 Screening and Treatment for Group B Streptococcus in Pregnancy , RANZCOG statement C-Obs 19 Melbourne: Royal Australian and New Zealand College of Obstetricians and Gynaecologists;
    [Google Scholar]
  27. Schrag S., Gorwitz R., Fultz-Butts K., Schuchat A. 2002; Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 51:1–22
    [Google Scholar]
  28. Stylianopoulos A., Kelly N., Garland S. 2002; Is penicillin and/or erythromycin resistance present in clinical isolates of group B streptococcus in our community?. Aust N Z J Obstet Gynaecol 42:543–544 [CrossRef]
    [Google Scholar]
  29. Uh Y., Hwang G. Y., Jang I. H., Kwon O., Kim H. Y., Yoon K. J. 2007; Antimicrobial susceptibility patterns and macrolide resistance genes of β -hemolytic viridans group streptococci in a tertiary Korean hospital. J Korean Med Sci 22:791–794 [CrossRef]
    [Google Scholar]
  30. Wendel G. D. Jr, Leveno K. J., Sanchez P. J., Jackson G. L., McIntire D. D., Siegel J. D. 2002; Prevention of neonatal group B streptococcal disease: a combined intrapartum and neonatal protocol. Am J Obstet Gynecol 186:618–626 [CrossRef]
    [Google Scholar]
  31. Zeng X., Kong F., Wang H., Darbar A., Gilbert G. L. 2006; Simultaneous detection of nine antibiotic resistance-related genes in Streptococcus agalactiae using multiplex PCR and reverse line blot hybridization assay. Antimicrob Agents Chemother 50:204–209 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.022616-0
Loading
/content/journal/jmm/10.1099/jmm.0.022616-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error